Tenon Medical raises $3M in private placement to fund SI joint devices

What's the deal? Tenon MedicalDealroom has a profile for this one. Try Dealroom → (NASDAQ:TNON), a Los Gatos, California medical device company, has agreed to sell shares and warrants to an institutional investor in a private placement expected to raise about $3 million in gross proceeds. The company entered the securities purchase agreement on August 27, 2026, and expects to close on or about August 31.

The terms: Tenon will issue 597,610 shares of common stock (or pre-funded warrants in lieu), plus warrants to purchase up to 1,058,517 additional shares. The warrants are immediately exercisable and expire five years from issuance.

Who's involved? WallachBeth CapitalDealroom has a profile for this one. Try Dealroom → is acting as exclusive placement agent. The offering is being made under Section 4(a)(2) of the Securities Act, and the securities have not been registered.

What's the endgame? Tenon builds systems to treat diseased sacroiliac (SI) joints. It sells The Catamaran SI Joint Fusion System, a less invasive approach using a single titanium implant, launched nationally in October 2022.

In August 2025, Tenon acquired substantially all the assets of SiVantageDealroom has a profile for this one. Try Dealroom → and SIMPL MedicalDealroom has a profile for this one. Try Dealroom →, adding the SImmetry+ SI Joint Fusion System, a minimally invasive lateral access solution. The company now targets three commercial opportunities: primary SI joint procedures, revisions of failed implants, and SI joint fusion as an adjunct to spine fusion.

The signal: Small-cap medical device firms increasingly turn to private placements for near-term capital as public markets stay tight. For Tenon, the $3 million injection follows a year of acquisition-driven expansion, giving it fresh runway to scale two commercial systems in a niche surgical market.

Image credit: NavyMedicine